Pathak SJ, Mueller JL, Okamoto K, et al. *EPCAM* mutation update: Variants associated with congenital tufting enteropathy and Lynch syndrome. Human Mutation. 2019;40:142--161. 10.1002/humu.23688 30461124

Communicated by Rolf H. Sijmons

1. BACKGROUND {#humu23688-sec-0010}
=============

Epithelial cellular adhesion molecule (*EPCAM*, formerly known as *TACSTD1* or *TROP1*; MIM\# 185535) encodes the EpCAM protein, which is normally expressed on the basolateral membrane of cells in epithelial tissues and on plasma cells and was originally identified as a tumor antigen (Bergsagel, Victor‐Kobrin, Timblin, Trepel, & Kuehl, [1992](#humu23688-bib-0010){ref-type="ref"}; Herlyn, Steplewski, Herlyn, & Koprowski, [1979](#humu23688-bib-0038){ref-type="ref"}; Litvinov, Bakker, Gourevitch, Velders, & Warnaar, [1994](#humu23688-bib-0060){ref-type="ref"}; Litvinov, Velders, Bakker, Fleuren, & Warnaar, [1994](#humu23688-bib-0062){ref-type="ref"}). Mutations in *EPCAM* have been linked to two distinct diseases, congenital tufting enteropathy (CTE) and Lynch syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC).

1.1. *EPCAM* in CTE {#humu23688-sec-0020}
-------------------

Biallelic inactivation of *EPCAM* (Sivagnanam et al., [2008](#humu23688-bib-0101){ref-type="ref"}) causes CTE (MIM\# 613217), which is a rare autosomal recessive diarrheal disorder (Reifen, Cutz, Griffiths, Ngan, & Sherman, [1994](#humu23688-bib-0087){ref-type="ref"}) with an estimated incidence of one in 50,000--100,000 births based on a study in Western Europe (Goulet, Salomon, Ruemmele, de Serres, & Brousse, [2007](#humu23688-bib-0032){ref-type="ref"}). In addition to being caused by *EPCAM* mutations (Sivagnanam et al., [2008](#humu23688-bib-0101){ref-type="ref"}), mutations in *SPINT2* (MIM\# 605124) have been implicated in a syndromic form of the disease (Salomon et al., [2014](#humu23688-bib-0092){ref-type="ref"}), which may cause an indirect loss of EpCAM protein due to proteolysis by activation of matriptase (Wu, Feng, Lu, Morimura, & Udey, [2017](#humu23688-bib-0131){ref-type="ref"}). CTE presents within the first months of life with severe chronic watery diarrhea and growth restriction. CTE patients require rapid diagnosis and often immediate total parenteral nutrition (TPN) therapy to sustain adequate caloric and fluid intake, and to prevent mortality by effectively bypassing the gut (Beck, Kang, & Suh, [2001](#humu23688-bib-0008){ref-type="ref"}; Goulet et al., [2007](#humu23688-bib-0032){ref-type="ref"}). This disease most often leads to intestinal failure and lack of enteral autonomy, although favorable outcomes have been reported in some patients (Lemale et al., [2011](#humu23688-bib-0056){ref-type="ref"}). The current diagnostic criteria include total or partial villus atrophy and crypt hyperplasia typically without evidence of inflammation, in addition to characteristic focal epithelial tufts composed of enterocytes with plasma membrane rounding found in the duodenum and jejunum (Sherman, Mitchell, & Cutz, [2004](#humu23688-bib-0099){ref-type="ref"}). The focal epithelial tufts distinguish CTE from the other two congenital enteropathies directly affecting enterocytes: (1) microvillous inclusion disease (MIM\# 251850), which is caused by homozygous or compound heterozygous mutations in *MYO5B* and is characterized by Periodic Acid‐Schiff positive inclusion bodies in the context of microvillous atrophy (Cutz et al., [1989](#humu23688-bib-0016){ref-type="ref"}), and (2) tricho‐hepato‐enteric syndrome (MIM\# 222470 and MIM\# 614602), which is caused by homozygous or heterozygous mutations in *TTC37* or *SKIV2L* and is characterized by facial dysmorphism, hair abnormalities, intrauterine growth restriction, and immune deficiency (Verloes et al., [1997](#humu23688-bib-0123){ref-type="ref"}).

1.2. *EPCAM* in Lynch syndrome {#humu23688-sec-0030}
------------------------------

In contrast to the biallelic inactivation of *EPCAM* in CTE, monoallelic deletions of the last exons of *EPCAM* give rise Lynch syndrome in 1--3% of affected families (Kovacs, Papp, Szentirmay, Otto, & Olah, [2009](#humu23688-bib-0051){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}). Lynch syndrome (MIM\# 120435) is an autosomal dominant disease that predisposes patients to early onset colorectal and endometrial cancers (Lynch et al., [2009](#humu23688-bib-0064){ref-type="ref"}). Lynch syndrome is caused by inheritance of one defective allele in a DNA mismatch repair (MMR) gene, which is a pathway that primarily acts to repair errors made during replication (Kolodner, [2016](#humu23688-bib-0050){ref-type="ref"}). Inheritance of two defective alleles of a MMR gene, however, does not cause Lynch syndrome but rather causes constitutional MMR deficiency (CMMR‐D also called biallelic MMR deficiency and MMR cancer syndrome; MIM\# 276300), which is associated with blood‐borne cancers, central nervous system cancers, and colorectal tumors usually occurring in the first two decades of life (Shlien et al., [2015](#humu23688-bib-0100){ref-type="ref"}). Remarkably, Lynch syndrome is caused by defects in only a few of the genes involved in MMR, predominantly *MSH2* and *MLH1*, although carriers of *PMS2* and *MSH6* mutations also have Lynch syndrome though with a milder phenotype than carriers of *MSH2* or *MLH1* defects (Lynch et al., [2009](#humu23688-bib-0064){ref-type="ref"}).

Cancer predisposition in Lynch syndrome patients is due to a secondary somatic inactivation of the functional MMR allele (Hemminki et al., [1994](#humu23688-bib-0037){ref-type="ref"}). These tumors have strong mutator phenotype and are clinical recognized by the instability of the number of copies of microsatellite repeats (a microsatellite instability high or MSI‐H phenotype). Lynch syndrome was traditionally suspected in patients presenting with colon cancer before age 50, or a family history colon or uterine cancer at a young age. The Amsterdam I and II criteria, and more recently, the Bethesda and the revised Bethesda guidelines, propose to identify individuals who were likely to be mutation carriers for Lynch syndrome (Giardiello et al., [2014](#humu23688-bib-0029){ref-type="ref"}). These guidelines identify individuals with colorectal cancer and endometrial cancer who should undergo tumor testing for a MSI‐H phenotype and immunohistochemical detection of MMR proteins, as well as testing for mutations in MMR genes (Wimmer & Etzler, [2008](#humu23688-bib-0129){ref-type="ref"}; Zeinalian, Hashemzadeh‐Chaleshtori, Salehi, & Emami, [2018](#humu23688-bib-0134){ref-type="ref"}). Once Lynch syndrome is identified, each case belongs to a family that requires genetic counseling, DNA testing for the detected mutation, and screening for colorectal cancer. Colonoscopy is the mainstay of colorectal cancer surveillance, particularly given that 70--80% of tumors are found proximal to the splenic flexure. The average age of colorectal cancer due to Lynch syndrome is 45 years, thus screening colonoscopy for Lynch syndrome patients is recommended at age 25 and repeated every 1 to 2 years. If patients are found to have colorectal cancer, subtotal colectomy may be necessary, given the marked frequency of synchronous and metachronous colorectal cancers (Lynch et al., [2009](#humu23688-bib-0064){ref-type="ref"}).

*EPCAM*‐associated Lynch syndrome is not due to loss of *EPCAM* per se, but rather is due to monoallelic inactivation of the downstream *MSH2* gene (MIM\# <http://609309>) by methylation in the CpG island that harbors the promoter and start site of *MSH2* (Fishel et al., [1993](#humu23688-bib-0022){ref-type="ref"}). A causative role for silencing *MSH2* in Lynch syndrome in patients with germline 3′ deletions of *EPCAM* has been demonstrated by the fact that second hits in tumors arise from somatic variants that affect the unsilenced copy of *MSH2* and are associated with the loss of the MSH2 protein (Eguchi et al., [2016](#humu23688-bib-0020){ref-type="ref"}; Huth et al., [2012](#humu23688-bib-0043){ref-type="ref"}; Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}; Spaepen et al., [2013](#humu23688-bib-0107){ref-type="ref"}). Moreover, the presence of multiple Alu sequences from the 3′ end of *EPCAM* to the middle of *MSH2* can lead to internal recombination events and deletions of portions of *MSH2* (Hitchins & Burn, [2011](#humu23688-bib-0039){ref-type="ref"}; Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}; van der Klift et al., [2005](#humu23688-bib-0120){ref-type="ref"}). Losses of only the polyadenylation signal of *EPCAM*, but not the promoter or start site of *MSH2*, leads to a Lynch syndrome‐*MSH2* phenotype in those tissues that express *EPCAM*, and may present clinically as a colon cancer‐only phenotype (Lynch et al., [2011](#humu23688-bib-0065){ref-type="ref"}).

In summary, depending on the type of mutations of *EPCAM*, biallelic or monoallelic, two very distinct clinical phenotypes may occur.

2. BIOLOGICAL ROLE OF *EPCAM* {#humu23688-sec-0040}
=============================

In normal tissues, human EpCAM is expressed on the surface of simple, pseudo‐stratified, and transitional epithelia in various tissues of the gastrointestinal tract, reproductive system, and respiratory tract. EpCAM has been implicated in a variety of important cellular functions including cell proliferation, migration, adhesion, differentiation, and cell signaling (Balzar et al., [1999](#humu23688-bib-0005){ref-type="ref"}; Litvinov et al., [1997](#humu23688-bib-0061){ref-type="ref"}; Trzpis, McLaughlin, de Leij, & Harmsen, [2007](#humu23688-bib-0116){ref-type="ref"}; Tsaktanis et al., [2015](#humu23688-bib-0118){ref-type="ref"}; Winter et al., [2003](#humu23688-bib-0130){ref-type="ref"}). EpCAM was first recognized as an antigen overexpressed on human carcinoma cells, including tumors of the gastrointestinal system, breast, thyroid, and kidney (Balzar, Winter, De Boer, & Litvinov, [1999](#humu23688-bib-0006){ref-type="ref"}). Decreased and altered EpCAM expression has been described in ulcerative colitis patients where altered intestinal barrier function is a major characteristic (Furth et al., [2006](#humu23688-bib-0025){ref-type="ref"}). EpCAM expression is tightly regulated during embryogenesis, and spatiotemporal patterning of EpCAM has recently been shown to be important for embryonic endodermal and mesodermal differentiation (Sarrach et al., [2018](#humu23688-bib-0093){ref-type="ref"}).

EpCAM has long been described as a cell adhesion molecule that mediates cell--cell interactions through homooligomerization (Balzar et al., [1999](#humu23688-bib-0005){ref-type="ref"}; Litvinov et al., [1997](#humu23688-bib-0061){ref-type="ref"}). In contrast, recent experiments have not been able to demonstrate EpCAM protein oligomerization in vitro and have not observed a role for EpCAM in the adhesion of carcinoma cell lines (Gaber et al., [2018](#humu23688-bib-0026){ref-type="ref"}; Tsaktanis et al., [2015](#humu23688-bib-0118){ref-type="ref"}). Additionally, EpCAM expression weakens cadherin‐mediated cell adhesion and promotes cell migration and cell invasion in a breast cancer cell line (Osta et al., [2004](#humu23688-bib-0077){ref-type="ref"}; Winter et al., [2003](#humu23688-bib-0130){ref-type="ref"}). These more recent observations have led to the hypothesis that EpCAM requires a ligand for oligomerization or that EpCAM is not a cell adhesion molecule. Intriguingly, EpCAM lacks structural similarity with other known cell adhesion molecules, and the closely related homolog encoded by *TACSTD2/TROP2* (MIM\# 137290) does not mediate cell--cell interactions (Fornaro et al., [1995](#humu23688-bib-0024){ref-type="ref"}; Gaber et al., [2018](#humu23688-bib-0026){ref-type="ref"}). Unlike *EPCAM*, homozygous and compound heterozygous mutations in the *TACSTD2* gene do not have an intestinal phenotype, but rather give rise to gelatinous drop‐like corneal dystrophy (MIM\# 204870; Ren et al., [2002](#humu23688-bib-0088){ref-type="ref"}; Tsujikawa et al., [1999](#humu23688-bib-0119){ref-type="ref"}).

In spite of the controversy regarding specific role of EpCAM in mediating cell--cell by homooligomerization, a physical interaction between EpCAM and Claudin‐7, which is a component of tight junctions, has been demonstrated (Ladwein et al., [2005](#humu23688-bib-0054){ref-type="ref"}; Wu et al., [2017](#humu23688-bib-0131){ref-type="ref"}), and EpCAM contributes to formation of the intestinal barrier by recruiting claudins to cell--cell junctions (Lei et al., [2012](#humu23688-bib-0055){ref-type="ref"}). In normal intestines, Claudin‐7 forms a stable protein complex with EpCAM, whereas CTE‐associated *EPCAM* mutations lead to instability of the EpCAM--Claudin‐7 interaction, decreasing its presence on the plasma membrane (Mueller, McGeough, Pena, & Sivagnanam, [2014](#humu23688-bib-0070){ref-type="ref"}). In addition to the critical role EpCAM plays in maintenance of the intestinal barrier, EpCAM has potent effects on cell proliferation and differentiation (Tsaktanis et al., [2015](#humu23688-bib-0118){ref-type="ref"}). EpCAM appears to play a role in morphogenesis and development of some tissues. In renal tissue, EpCAM is upregulated postischemia in murine models and thus may have a role in regeneration (Trzpis et al., [2007](#humu23688-bib-0116){ref-type="ref"}; Trzpis et al., [2008](#humu23688-bib-0117){ref-type="ref"}). In the pancreas, EpCAM is involved in islet development (Cirulli, Ricordi, & Hayek, [1995](#humu23688-bib-0015){ref-type="ref"}; Vercollone, Balzar, Litvinov, Yang, & Cirulli, [2015](#humu23688-bib-0122){ref-type="ref"}); however, its function during gut formation has not yet been elucidated. Despite the ubiquity of EpCAM in various tissues, the primary symptoms of CTE patients are due to intestinal defects and other systemic defects are not typically reported. EpCAM\'s biologic role is multifaceted and fully understanding its part in health and disease remains a topic of ongoing investigation.

3. VARIANTS OF *EPCAM* IN HUMAN DISEASE {#humu23688-sec-0050}
=======================================

The past decade has seen advances in our understanding of the genetics of *EPCAM*. CTE‐causing biallelic *EPCAM* mutations are predicted to disrupt the expression and/or stability of the EpCAM protein, whereas Lynch syndrome is caused by monoallelic mutations affecting downstream *MSH2*. We present here novel CTE‐causing variants of *EPCAM* and review all known variants in relation to these disease processes.

3.1. Novel variants of *EPCAM* in CTE {#humu23688-sec-0060}
-------------------------------------

To identify additional CTE‐causing *EPCAM* variants, 17 CTE patients were recruited from around the world to the University of California, San Diego (UCSD) and the University of California, Los Angeles (UCLA). Informed consent of the subjects was obtained according to the Institutional Review Board guidelines at UCSD and UCLA. Phenotypic data were ascertained. Exons of the *EPCAM* gene were amplified by polymerase chain reaction from patient genomic DNA and subjected to Sanger sequencing as previously described (Sivagnanam et al., [2008](#humu23688-bib-0101){ref-type="ref"}; Sivagnanam et al., [2010](#humu23688-bib-0102){ref-type="ref"}).

Of the 17 newly identified patients, there were 11 males, five females, and the gender of one patient was not obtained. The disease outcomes included: 10 patients treated with full TPN, four patients treated with partial TPN, and two patients weaned off TPN (one due to limited vascular access); the treatment of one patient was unknown. No patients underwent bowel transplantation or were deceased. Nine patients were compound heterozygotes and eight were homozygotes for mutations in *EPCAM* (Table [1](#humu23688-tbl-0001){ref-type="table"}).

###### 

Novel variants of *EPCAM* in CTE patients

  Patient[\*\*](#humu23688-tbl1-note-0001){ref-type="fn"}   Coding DNA                  Protein                                                            Type of mutation                   Zygosity                Ethnicity         Gender    TPN requirement                 Transplant
  --------------------------------------------------------- --------------------------- ------------------------------------------------------------------ ---------------------------------- ----------------------- ----------------- --------- ------------------------------- ------------
  1                                                         c.113G\>A; c.48_68del21     p.(C38Y); p.(A18_Q24del)                                           Missense; in‐frame deletion        Compound heterozygous   Caucasian         M         Full TPN                        No
  2                                                         c.1A\>C; c.38_62dup25       p.(M1L); p.(A22Cfs\*17)                                            Missense; frameshift               Compound heterozygous   Palestinian       F         Off TPN due to limited access   No
  3                                                         c.267G\>C; c.\*118T\>C      p.(Q89H); unknown consequence                                      Missense; unknown                  Compound heterozygous   English           M         Full TPN                        No
  4                                                         c.307G\>A; c.492‐5T\>C      p.(G103R); splicing defect                                         Missense; splicing defect          Compound heterozygous   English‐Italian   M         Partial TPN                     No
  5.1                                                       c.491+1G\>A; c.556‐14A\>G   p.(W143_T164del) \[del exon 4\]; p.(Y186_D219del\*)                Splicing defect; splicing defect   Compound heterozygous   Bangladeshi       M         Full TPN                        No
  5.2                                                       c.491+1G\>A; c.556‐14A\>G   p.(W143_T164del) \[del exon 4\]; p.(Y186_D219del\*)                Splicing defect; splicing defect   Compound heterozygous   Bangladeshi       M         Full TPN                        No
  6                                                         c.492‐1G\>A; c.491+1G\>A    p.(W143_T164del) \[del exon 4\]; p.(W143_T164del) \[del exon 4\]   Splicing defect; splicing defect   Compound heterozygous   Hispanic          M         Full TPN                        No
  7                                                         c.509_511delTCA             p.(I170del)                                                        In‐frame deletion                  Homozygous              Pakistani         Unknown   Unknown                         Unknown
  8                                                         c.555+1G\>C                 p.(A65Mfs\*23) \[del exon 5\]                                      Splicing defect                    Homozygous              Turkish           F         Weaned off                      No
  9.1                                                       c.579delT                   p.(I193Mfs\*17)                                                    Frameshift                         Homozygous              Bedouin           M         Full TPN                        No
  9.2                                                       c.579delT                   p.(I193Mfs\*17)                                                    Frameshift                         Homozygous              Bedouin           F         Full TPN                        No
  10                                                        c.589C\>T                   p.(Q197\*)                                                         Truncation                         Homozygous              Iraqi             M         Full TPN                        No
  11.1                                                      c.540delT; c.491+1G\>A      p.(F180Lfs\*30); p.(W143_T164del) \[del exon 4\]                   Frameshift; splicing defect        Compound heterozygous   Unknown           M         Partial TPN                     No
  11.2                                                      c.540delT; c.491+1G\>A      p.(F180Lfs\*30); p.(W143_T164del) \[del exon 4\]                   Frameshift; Splicing defect        Compound heterozygous   Unknown           M         Partial TPN                     No
  12                                                        c.757G\>A                   p.(D253N)                                                          Missense                           Homozygous              Turkish           M         Full TPN                        No
  13                                                        g.29411_34526del5116        p.(Q24_Y142del)                                                    Deletion                           Homozygous              Hispanic          F         Partial TPN                     No
  14                                                        c.227C\>G                   p.(S76\*)                                                          Truncation                         Homozygous              Israeli           F         Full TPN                        No

\*\*Siblings are annotated with decimals, e.g. patients 5.1 and 5.2.

John Wiley & Sons, Ltd.

A total of 19 distinct *EPCAM* mutations were observed, and 13 of these mutations have not been previously reported (c.1A\>C, c.113G\>A, c.227C\>G, c.267G\>C, c.589C\>T, c.757G\>A, c.540delT, c.579delT, c.38_62dup25, c.48_68del21, c.509_511delTCA, c.492‐5T\>C \[NC_000002.12:g.47377009T\>C\], c.\*118T\>C, and a deletion spanning the end of exon 1 and intron 3--4, NG_012352.2:g.29411_34526del5116, which generates p.Q24_Y142del; note that coding mutations are reported relative to the *EPCAM* reference sequence NM_002354.2). None of the novel *EPCAM* mutations were observed more than once outside of individual families or in homozygous patients. This pattern is consistent with CTE affecting children of families that carry rare recessive *EPCAM* mutations and does not provide evidence for a founder effect in these patient cohorts, unlike that observed in some patients of Kuwaiti and Middle Eastern origin (Salomon et al., [2011](#humu23688-bib-0091){ref-type="ref"}).

3.2. Reported variants in *EPCAM* in CTE {#humu23688-sec-0070}
----------------------------------------

An analysis of the 72 previously reported CTE patients (AlMahamed & Hammo, [2017](#humu23688-bib-0002){ref-type="ref"}; Al‐Mayouf, Alswaied, Alkuraya, AlMehaidib, & Faqih, [2009](#humu23688-bib-0001){ref-type="ref"}; Bodian et al., [2017](#humu23688-bib-0011){ref-type="ref"}; d\'Apolito et al., [2016](#humu23688-bib-0017){ref-type="ref"}; Ko et al., [2010](#humu23688-bib-0048){ref-type="ref"}; Pêgas et al., [2014](#humu23688-bib-0081){ref-type="ref"}; Salomon et al., [2011](#humu23688-bib-0091){ref-type="ref"}; Salomon et al., [2014](#humu23688-bib-0092){ref-type="ref"}; Schnell et al., [2013](#humu23688-bib-0095){ref-type="ref"}; Shakhnovich, Dinwiddie, Hildreth, Attard, & Kingsmore, [2017](#humu23688-bib-0098){ref-type="ref"}; Sivagnanam et al., [2008](#humu23688-bib-0101){ref-type="ref"}; Sivagnanam et al., [2010](#humu23688-bib-0102){ref-type="ref"}; Tang, Huang, Xu, & Huang, [2018](#humu23688-bib-0111){ref-type="ref"}; Thoeni et al., [2014](#humu23688-bib-0113){ref-type="ref"}) along with the 17 novel patients reported here is consistent with the expected genetics of an autosomal recessive disease (Figure [1](#humu23688-fig-0001){ref-type="fig"}; Supporting Information Table [1](#humu23688-supl-0002){ref-type="supplementary-material"}). Many CTE patients (60 of 90 patients) were homozygous for *EPCAM* mutations, and most of the remainder were compound heterozygotes (24 of 90 patients). The large proportion of homozygote individuals is consistent with the high incidence of CTE patients amongst consanguineous families (21 of the 30 cases where information was available) and/or were consistent with founder effects, as has been previously reported (Salomon et al., [2011](#humu23688-bib-0091){ref-type="ref"}). Additionally, for the 88 patients where gender was known (50 males and 38 females), there was no bias (*P* = 0.36, chi‐squared test). The majority of patients are Middle Eastern in descent, though several other ethnicities were represented, including Caucasian and Hispanic.

![Quantitative distribution of *EPCAM* mutations identified in CTE patients. Each patient is represented by a single box. Gray boxes correspond to the presence of the mutation in homozygous patients, whereas white boxes correspond to the presence of a mutation in heterozygous patients](HUMU-40-142-g001){#humu23688-fig-0001}

The 90 reported CTE patients implicate 42 distinct *EPCAM* mutations in causing CTE (Figures [2](#humu23688-fig-0002){ref-type="fig"}a and [2](#humu23688-fig-0002){ref-type="fig"}b). These mutations include six chromosomal deletions, eight noncoding/splicing mutations, 16 frameshifts/nonsense mutations that would lead to EpCAM truncation, and 12 missense mutations or in‐frame deletions. Only four mutations have been reported in five or more patients: c.499dupC (previously reported as c.498insC; 28 patients, 23 homozygotes), c.556‐14A\>G (14 patients, six homozygotes), c.491+1G\>A (nine patients, two homozygotes), and c.492‐2A\>G (seven patients, two homozygotes).

![Reported mutations in *EPCAM* identified in CTE patients. (a) Reported mutations are shown based on their effect on the gene (top), mRNA (middle), or protein (bottom). (b) The positions of missense mutations are depicted on the EPCAM dimer structure; theoretical membrane and transmembrane helix structures are shown to indicate protein orientation](HUMU-40-142-g002){#humu23688-fig-0002}

3.3. Reported variants of *EPCAM* in Lynch syndrome {#humu23688-sec-0080}
---------------------------------------------------

The *EPCAM* gene is 17 kb upstream of the *MSH2* gene on the short arm of human chromosome 2. The first evidence that large deletions upstream of the *MSH2* gene could give rise to Lynch syndrome was reported in families from Swiss and American populations (van der Klift et al., [2005](#humu23688-bib-0120){ref-type="ref"}). Around the same time, heritable hypermethylation of the *MSH2* promoter, which was the highest in colonic mucosa and colon tumors but lowest in blood leukocytes, was reported (Chan et al., [2006](#humu23688-bib-0012){ref-type="ref"}). These two observations turned out to be linked, as monoallelic deletions of the 3′ end of the *EPCAM* gene in which the polyadenylation signal is lost give rise to *MSH2* promoter hypermethylation, read‐through transcription of the *EPCAM* and *MSH2* genes, and loss of MSH2 protein expression (Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}). As these 3′ *EPCAM* deletions are germline variants, the promoter methylation is heritable and has been termed an "epimutation," which has also been associated with the *MLH1* promoter in at least one case of Lynch syndrome (Gazzoli, Loda, Garber, Syngal, & Kolodner, [2002](#humu23688-bib-0028){ref-type="ref"}). In some of the observed *EPCAM‐MSH2* fusion transcripts, a cryptic exon in the intergenic region between *EPCAM* and *MSH2* was present in the transcript (Gazzoli et al., [2002](#humu23688-bib-0028){ref-type="ref"}; Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}).

Twenty‐five 3′ deletions of *EPCAM* characterized at the sequence level have been implicated in causing Lynch syndrome (Dymerska et al., [2017](#humu23688-bib-0019){ref-type="ref"}; Eguchi et al., [2016](#humu23688-bib-0020){ref-type="ref"}; Guarinos et al., [2010](#humu23688-bib-0033){ref-type="ref"}; Huth et al., [2012](#humu23688-bib-0043){ref-type="ref"}; Kempers et al., [2011](#humu23688-bib-0046){ref-type="ref"}; Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}; Kuiper et al., [2011](#humu23688-bib-0053){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}; Lynch et al., [2011](#humu23688-bib-0065){ref-type="ref"}; Mur et al., [2014](#humu23688-bib-0072){ref-type="ref"}; Nagasaka et al., [2010](#humu23688-bib-0075){ref-type="ref"}; Niessen et al., [2009](#humu23688-bib-0076){ref-type="ref"}; Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}; Rossi et al., [2017](#humu23688-bib-0089){ref-type="ref"}; Rumilla et al., [2011](#humu23688-bib-0090){ref-type="ref"}; Spaepen et al., [2013](#humu23688-bib-0107){ref-type="ref"}; van der Klift et al., [2005](#humu23688-bib-0120){ref-type="ref"}). Most of these deletions are mediated by recombination between imperfectly homologous *Alu* repeats (Figure [3](#humu23688-fig-0003){ref-type="fig"}a), which are a class of short repeats (∼300 bp) present in \>10^6^ copies in the human genome (Deininger, [2011](#humu23688-bib-0018){ref-type="ref"}). The length of the microhomologies at the breakpoint junction has been emphasized previously (Kuiper et al., [2011](#humu23688-bib-0053){ref-type="ref"}; van der Klift et al., [2005](#humu23688-bib-0120){ref-type="ref"}); however, even the shorter microhomology junctions are in the context of the larger *Alu* repeat homology (Figure [3](#humu23688-fig-0003){ref-type="fig"}a). Consistent with this, *Alu* sequences on the + strand only recombine with other *Alu* sequences on + strand, and the same is true for *Alu* sequences on the -- strand.

![3′ deletions of EPCAM associated with Lynch syndrome. (a) Illustration of the homologies of two *Alu*--*Alu* recombination events causing deletions of *EPCAM* exons 8 and 9. The top and bottom sequences correspond to the two *Alu* sequences involved in the recombination event, and the middle sequence is the novel junction. The sequences between the colons correspond to the identical microhomology at the deletion junction. (b) Diagram of the *EPCAM* deletions. Exons 1--9 of *EPCAM* and the first four exons of *MSH2* are depicted at the top. Deletions are shown in the middle as thick black lines. The *Alu* repeats involved at the homology‐mediated rearrangements for each deletion are shown as labeled black boxes; black boxes above the deletion line are *Alu* sequences encoded on the + strand, whereas black boxes below the deletion line are *Alu* sequences encoded on the -- strand. Repetitive elements on the + and -- strand identified by RepeatMasker version 406 ([Smit, 2013--2015](#humu23688-bib-0104){ref-type="ref"}) with the Repeat Library Version 20150807 are shown at bottom. *Alu*‐related sequences are shown as grey and black boxes; other repeats are shown as white boxes. Note that some deletions have previously been reported under different annotations: c.426‐544\_\*3904del (c.423‐545\_\*3903del), c.555+402\_\*1220del (AC079775.6:g.72468_82822del10355), c.555+927\_\*14226del (c.555+894\_\*14194del), c.858+1211\_\*4529del (c.85811211_4529del), c.858+1358\_\*4793del_insAG (c.858+1364\_\*4793del_insAG), c.858+2478\_\*4507del (AC079775.6:g.77436_86109del8674), c.859‐2524\_\*10762del (AC079775.6:g.77631_92364del14734), c.859‐1605\_\*5826del (c.859‐1605\_\*5862del), c.859‐696\_\*3914del (AC079775.6:g.79459_85516del6058), c.859‐692\_\*1990del (c.859‐672\_\*2170del), c.859‐689\_\*14697del (AC079775.6:g.79465_96299del16834), and c.859‐645\_\*10911del (AC079775.6:g.79509_92513del13004). In addition, two deletions reported as annotations but not with sequence do not support the reported junction microhomologies: c.492‐509\_\*13721del and c.858‐353\_\*618del](HUMU-40-142-g003){#humu23688-fig-0003}

Twenty‐three of the characterized deletions span *EPCAM* exons 8 and 9 (Figure [3](#humu23688-fig-0003){ref-type="fig"}b; Supporting Information Table [2](#humu23688-supl-0003){ref-type="supplementary-material"}), which eliminates the 3′ polyadenylation signal and thereby leads to read‐through transcription of *MSH2* and hypermethylation of the *MSH2* promoter. The majority of the deletions only span exons 8 and 9 (Figure [3](#humu23688-fig-0003){ref-type="fig"}b), which includes the founder mutation in the Dutch population, *EPCAM* c.859‐1452\_\*1999del, (Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}; Lynch et al., [2011](#humu23688-bib-0065){ref-type="ref"}), a potential founder mutation in the Spanish population, *EPCAM* c.858+2568\_\*4596del (Guarinos et al., [2010](#humu23688-bib-0033){ref-type="ref"}; Mur et al., [2014](#humu23688-bib-0072){ref-type="ref"}), and a potential founder mutation in the Polish population, *EPCAM* c.858+2478\_\*4507del (Dymerska et al., [2017](#humu23688-bib-0019){ref-type="ref"}). In principal, only deletion of exon 9 is required to give rise to read‐through transcription of *MSH2*; however, no *Alu* repeats are present within intron 8 (Figure [3](#humu23688-fig-0003){ref-type="fig"}b), suggesting that the common codeletion of exons 8 and 9 is influenced not by a requirement for loss of exon 8 but by the genomic context that leads to *Alu*--*Alu* recombination events. In addition to deletions that only affect the 3′ end of *EPCAM*, two deletions spanning the 3′ end of *EPCAM* and the 5′ end of *MSH2* have also been identified (Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}; Sekine et al., [2017](#humu23688-bib-0096){ref-type="ref"}).

In addition to the disease‐causing variants reported here, some nonpathogenic variants have been reported in the HGMD (<http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EPCAM)> and Leiden Open Variant Database (LOVD) and are summarized in Supp. Table [3](#humu23688-supl-0004){ref-type="supplementary-material"}.

4. VARIANT DATABASE {#humu23688-sec-0090}
===================

A locus‐specific database in the LOVD for EpCAM was created in 2009 and is moderated by Joh Paul Plazzer, Johan den Dunnen, and Mamata Sivagnanam (<https://databases.lovd.nl/shared/variants/EPCAM>). All previously published and novel mutations were recorded after performing a literature search for patients with CTE or Lynch syndrome in whom a variant in the *EPCAM* gene was reported. *EPCAM* genotypes were recorded from the original publications when data were available. Adjustment of nomenclature of certain variations were made to ascertain that base pair and protein sequence numbering were based on the *EPCAM* reference sequence NM_002354.2.

5. *EPCAM* STRUCTURE AND FUNCTION {#humu23688-sec-0100}
=================================

The nine exons of the *EPCAM* gene encode a 314 amino acid transmembrane glycoprotein (Figure [2](#humu23688-fig-0002){ref-type="fig"}a). The extracellular portion of EpCAM and the signal peptide is encoded by exons 1 to 6 and is composed of an N‐terminal disulfide‐stabilized domain, a central thyroglobulin‐like domain, and a C‐terminal domain (Pavsic, Guncar, Djinovic‐Carugo, & Lenarcic, [2014](#humu23688-bib-0080){ref-type="ref"}). The N‐terminal disulfide‐stabilized domain has previously been described as an "EGF‐like" domain, as the domain was predicted to contain beta‐strands and disulfides; however, the structure reveals that it has a disulfide bonding pattern more similar to the Cripto/Fri‐1/Cryptic domain of mouse Cripto and a fold more similar to WW domains, which was named due to two conserved tryptophan residues (Pavsic et al., [2014](#humu23688-bib-0080){ref-type="ref"}). We therefore term this domain the N‐terminal domain in this review, consistent with the terminology in the report of the EpCAM crystal structure (Pavsic et al., [2014](#humu23688-bib-0080){ref-type="ref"}). The thyroglobulin‐like domain has also been referred to as a second "EGF‐like" domain; however, the similarity with thyroglobulin was recognized some time ago and verified by the EpCAM structure (Baeuerle & Gires, [2007](#humu23688-bib-0004){ref-type="ref"}; Pavsic et al., [2014](#humu23688-bib-0080){ref-type="ref"}). The transmembrane portion is coded by exon 7, and the intracellular domain is encoded by exons 8 and 9 (last 13 amino acids; Balzar et al., [1999](#humu23688-bib-0005){ref-type="ref"}).

5.1. Predicted structural effects of *EPCAM* variants in CTE {#humu23688-sec-0110}
------------------------------------------------------------

In general, the *EPCAM* mutations found in CTE patients appear to be broadly inactivating. The large chromosomal truncations (6 of 41 mutations) give rise to variants that primarily lack most of the N‐terminal extracellular region of EpCAM, whereas the frameshift and nonsense mutations (15 of 41 mutations) truncate the EpCAM prior to the transmembrane helix and C‐terminal intracellular region (Pavsic et al., [2014](#humu23688-bib-0080){ref-type="ref"}). A small number of mutations were short (\<30 bp) duplications or deletions (four of 41) or larger chromosomal deletions (six of 41). Three of these are in‐frame deletions: c.48_68del21 (p.A18_Q24del) disrupts the leader peptide targeting EpCAM to the plasma membrane; the c.509_511delTCA deletes I170, which forms part of the hydrophobic core of the C‐terminal domain; and the exon 1--4 fusion deletes the N‐terminal and thyroglobulin domains. In contrast, the majority of point mutations (31 of 41) were single base insertions, deletions, or changes, and most of these (21 of 31) gave rise to frameshifts, stop codons, or splicing defects. The impact of the observed mutations on the EpCAM protein has not yet been extensively studied, although c.491+1G\>A generates mRNA molecules lacking exon 4 and c.492‐2A\>G causes abnormal in‐frame skipping of exon five (Salomon et al., [2011](#humu23688-bib-0091){ref-type="ref"}; Sivagnanam et al., [2008](#humu23688-bib-0101){ref-type="ref"}).

Because the CTE‐associated deletion, frameshift, and splice site mutations in *EPCAM* appear to be loss of function mutations, we aimed to understand how the known amino acid substitution mutations could affect the EpCAM protein structure, as most of these have not been investigated experimentally. The nine *EPCAM* missense mutations encode single amino acid substitutions primarily affected the extracellular thyroglobulin homology domain and internal portions of the extracellular C‐terminal domain of EpCAM (Figures [2](#humu23688-fig-0002){ref-type="fig"}a and 2b), consistent with the hypothesis that defects in cell--cell interactions are causal in CTE. Several of the amino acid substitutions are poised to disrupt the disulfide bonding in EpCAM extracellular domains (Figure [2](#humu23688-fig-0002){ref-type="fig"}b). The c.113G\>A (p.C38Y) and c.197G\>A (p.C66Y) mutations eliminate cysteine residues involved directly at the disulfide bonds in the N‐terminal domain and the thyroglobulin homology domain (Figures [4](#humu23688-fig-0004){ref-type="fig"}a and 4b). Additionally, the c.314T\>G (p.F105C) mutation provides a competing cysteine that could isomerize the C66--C99 disulfide bond (Figure [4](#humu23688-fig-0004){ref-type="fig"}a). The c.307G\>A (p.G103R) mutation amino acid substitution is positioned to sterically disrupt the C66--C99 disulfide bond formation (Figure [4](#humu23688-fig-0004){ref-type="fig"}a). Other amino acid substitutions are positioned to locally disrupt aspects of the EpCAM structure: the c.437T\>A (p.I146N) mutation places a polar residue in a highly hydrophobic environment (Figure [4](#humu23688-fig-0004){ref-type="fig"}c), the c.359A\>T (p.N120I) and c.757G\>A (p.D253N) mutations affect residues that are at one of the two contact regions between the thyroglobulin homology domain and the C‐terminal domain (Figure [4](#humu23688-fig-0004){ref-type="fig"}d), and the c.380C\>T (p.T127I) mutation places a hydrophobic residue in a polar environment and would, at a minimum, disrupt the hydrogen bonding interactions maintained by the amino acid side chains in the wild‐type protein (Figure [4](#humu23688-fig-0004){ref-type="fig"}e).

![Detailed views of the positions of reported missense mutations in *EPCAM* and c.491+1G\>A. (a) The F105C and G103R amino acid substitutions are positioned to affect the C66--C99 disulfide bond through disulfide bond isomerization (F105C) or through steric interactions (G103R) as shown by the molecular surface of the arginine mutant that clashes with Y32. (b) The C38Y amino acid substitution disrupts one of the disulfides in the N‐terminal domain. (c) The I146N amino acid substitution places a polar residue within the hydrophobic core of the C‐terminal domain. (d) The N120I and D253N substitutions disrupt the side chain--main chain hydrogen bonds between the thyroglobulin‐like domain and the C‐terminal domain. (e) The T127I amino acid substitution would disrupt side chain--main chain interactions adjacent to the C118‐C135 sulfide bond in the thyroglobulin‐like domain. (f). The c.491+1G\>A splice site mutation that causes exon 4 skipping would delete a core region (red cartoon) of the C‐terminal domain](HUMU-40-142-g004){#humu23688-fig-0004}

5.2. Predicted structural effects of *EPCAM* variants in Lynch syndrome {#humu23688-sec-0120}
-----------------------------------------------------------------------

Most of the Lynch syndrome associated 3′ deletions of *EPCAM* involve deletions of exon 8 and 9. Based on the EpCAM protein structure, these deletions would be predicted to give rise to loss of intracellular portions of EpCAM while leaving the extracellular domains and most of the transmembrane domain intact (Figure [2](#humu23688-fig-0002){ref-type="fig"}a). However, it is unclear if these truncated EpCAM proteins are made, as read‐through transcription would also give rise to *EPCAM‐MSH2* fusions (often between *EPCAM* exon 7 and *MSH2* exon 2, although an *EPCAM* exon 5‐*MSH2* exon 2 fusion was observed with c.555+927\_\*14226del and c.556‐531\_\*872del) and *EPCAM*‐cryptic exon‐*MSH2* fusions (Eguchi et al., [2016](#humu23688-bib-0020){ref-type="ref"}; Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}; Ligtenberg et al., [2009](#humu23688-bib-0058){ref-type="ref"}; Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}; Spaepen et al., [2013](#humu23688-bib-0107){ref-type="ref"}). Most of the *EPCAM* exon 7‐*MSH2* exon 2 fusions and *EPCAM* exon 7‐cryptic exon‐*MSH2* exon 2 fusions lead to a premature stop in *MSH2* exon 2, likely leading to loss of the mRNA through nonsense‐mediated decay (Maquat, [2004](#humu23688-bib-0067){ref-type="ref"}). In contrast, some transcripts isolated from the c.859‐696\_\*3914del background involve an alternative splice site donor in *EPCAM* exon 7 and alternative splice site acceptors in *MSH2* exon 2, and at least one transcript leads to an in‐frame fusion (Kovacs et al., [2009](#humu23688-bib-0051){ref-type="ref"}). In the case of one deletion spanning *EPCAM* exons 6--9 and *MSH2* exons 1--2, a mislocalized cytoplasmic MSH2 protein was detected by immunohistochemistry (Sekine et al., [2017](#humu23688-bib-0096){ref-type="ref"}). Consistent with the possibility that many 3′ deletions of *EPCAM* do not produce truncated EpCAM proteins, tumors arising in *EPCAM*‐associated Lynch syndrome patients with a secondary loss of the wild‐type copy of *EPCAM* do not express EpCAM, as observed by immunohistochemistry (Huth et al., [2012](#humu23688-bib-0043){ref-type="ref"}; Kang et al., [2015](#humu23688-bib-0045){ref-type="ref"}; Kloor et al., [2011](#humu23688-bib-0047){ref-type="ref"}; Musulen et al., [2013](#humu23688-bib-0073){ref-type="ref"}). This study, however, does not confirm that loss of only exons 8 and 9 of *EPCAM* is inactivating, as the deletions were not mapped and the multiplex ligation‐dependent probe amplification (MLPA) protocol performed only tested exons 3, 8, and 9 of *EPCAM* for copy number changes. In contrast, a number of the larger 3′ deletions of *EPCAM* associated with Lynch syndrome (Figure [3](#humu23688-fig-0003){ref-type="fig"}b) would give rise to EpCAM truncations that overlap with those observed in CTE and hence can be reliably predicted to be inactivating.

Structural effects of EPCAM variants are diverse in nature and lead to the unique phenotypes of CTE versus Lynch syndrome.

6. ANIMAL MODELS {#humu23688-sec-0130}
================

EpCAM is highly conserved in mammals (Balzar et al., [1999](#humu23688-bib-0005){ref-type="ref"}; Bergsagel et al., [1992](#humu23688-bib-0010){ref-type="ref"}). The pattern of murine *Epcam* mRNA expression is similar to that of human *EPCAM*, with highest expression in the gut and lower levels in the kidneys, pancreas, mammary glands, thyroid, pituitary, salivary glands, lungs, and genitalia, consistent with its epithelial distribution (Nagao et al., [2009](#humu23688-bib-0074){ref-type="ref"}). EpCAM protein has also been identified on the surface of mouse embryonic, neonatal, and adult germ cells, as well as embryonic stem cells (Basak et al., [1998](#humu23688-bib-0007){ref-type="ref"}; Gonzalez, Denzel, Mack, Conrad, & Gires, [2009](#humu23688-bib-0031){ref-type="ref"}). In vivo roles for EpCAM have been investigated in two zebrafish knockout models, which demonstrated its function in epithelial morphogenesis and skin development (Slanchev et al., [2009](#humu23688-bib-0103){ref-type="ref"}; Villablanca et al., [2006](#humu23688-bib-0124){ref-type="ref"}). *Epcam* knockout was initially reported to cause embryonic lethality in mice (Nagao et al., [2009](#humu23688-bib-0074){ref-type="ref"}); however, three groups have reported viable *Epcam* knockouts (Gaiser et al. [2012](#humu23688-bib-0027){ref-type="ref"}; Guerra et al., [2012](#humu23688-bib-0034){ref-type="ref"}; Lei et al., [2012](#humu23688-bib-0055){ref-type="ref"}). Constitutive deletion of *Epcam* exons 2 and 3 caused intestinal defects and an inability of the mutant mice to gain weight and was associated with a failure to form functional tight junctions and defects in the recruitment of claudins in line with EpCAM\'s role of recruiting claudins to tight junctions in cellular models (Lei et al., [2012](#humu23688-bib-0055){ref-type="ref"}; Wu, Mannan, Lu, & Udey, [2013](#humu23688-bib-0132){ref-type="ref"}). Another viable knockout constructed by gene trapping revealed severe hemorrhagic enteropathy (Guerra et al., [2012](#humu23688-bib-0034){ref-type="ref"}). EpCAM mice models with neonatal intestinal abnormalities have suggested EpCAM affects cell--cell junctions through expression and localization of E‐cadherin and beta‐catenin, which are essential components of adherens junctions (Guerra et al., [2012](#humu23688-bib-0034){ref-type="ref"}), and decreased expression of tight junction proteins, increased permeability, and decreased ion transport in the intestines (Kozan et al., [2015](#humu23688-bib-0052){ref-type="ref"}). Additionally, a conditional knockout of *Epcam* in Langerhans cells demonstrated a role for EpCAM in promoting the motility and migration of these cells from the skin to the lymph nodes after activation (Gaiser et al., [2012](#humu23688-bib-0027){ref-type="ref"}). Constitutive and inducible CTE‐associated murine models express mutant EpCAM, lacking exon 4, rather than a gene knockout, and mimic CTE with growth retardation, and intestinal epithelial tufts. These models show enhanced intestinal permeability and migration as well as decreased ion transport and expression of tight junctional proteins (Kozan et al., [2015](#humu23688-bib-0052){ref-type="ref"}; Mueller et al., [2014](#humu23688-bib-0070){ref-type="ref"}).

7. GENOTYPE--PHENOTYPE CORRELATION {#humu23688-sec-0140}
==================================

The dramatically different phenotypes of CTE and Lynch syndrome provide a clear genotype--phenotype correlation: monoallelic 3′ deletion of *EPCAM* leading to loss of *MSH2* expression does not cause CTE, but does give rise to Lynch syndrome, whereas biallelic inactivation of *EPCAM* gives rise to CTE. As CTE is caused directly by loss‐of‐function *EPCAM* mutations, a large number of inactivating mutations can cause CTE without affecting expression of *MSH2* and hence do not cause Lynch syndrome or CMMR‐D. In principle, genotypes can be envisioned that combine both CTE and MMR defects. A combination of Lynch syndrome and CTE could theoretically arise in a heterozygote possessing a 3′ deletion of *EPCAM* that inactivates *MSH2* and another *EPCAM* inactivating mutation that does not inactivate *MSH2*. A combination of CMMR‐D and CTE could arise by germline biallelic inactivation of *EPCAM* via 3′ deletions that also lead to loss of *MSH2* expression. To date, no patient has been described with both CTE and Lynch syndrome or CMMR‐D, which may be due in part to the fact that Lynch syndrome is observed at an age past the typical lifespan of CTE patients. However, a 9‐year‐old patient with a heterozygous deletion of *EPCAM* and a heterozygous *MSH2* missense mutation was identified as having atypical CMMR‐D in which MSH2 was absent in an EpCAM expression‐dependent manner (Li‐Chang et al., [2013](#humu23688-bib-0057){ref-type="ref"}). This patient was not reported to have CTE, likely due to EpCAM expression from the normal allele.

7.1. Genotype--phenotype correlations in CTE {#humu23688-sec-0150}
--------------------------------------------

A wide range of alimentary needs were noted among the 68 reported CTE patients for whom nutritional data were available (Figure [5](#humu23688-fig-0005){ref-type="fig"}): four patients were weaned off TPN entirely; 16 patients had partial TPN ranging from 3 out of 7 (3/7) days to 6/7 days; and 48 patients were on full TPN (7/7 days). About one‐third of patients showed significant morbidity and mortality as 13 patients underwent transplant and 12 patients were deceased. Of the transplanted patients, four patients were deceased. We hypothesized these differential clinical outcomes, nutritional data/TPN status, need for bowel transplantation, and mortality, could be used as surrogate markers for disease severity. To examine these data for evidence of a genotype--phenotype correlation, patients were divided into genotypic groups in which *EPCAM* alleles were mapped to categories (frameshift mutation, nonsense mutation, missense mutation, and splicing defect). The nutritional requirements, need for bowel transplantation, and mortality for each genotypic group were then compared to the rest of the patients using the maximum likelihood *G*‐test (Supporting Information Table [3](#humu23688-supl-0004){ref-type="supplementary-material"}), which is more appropriate than the chi‐squared test for small sample sizes (Sokal, [1994](#humu23688-bib-0105){ref-type="ref"}). The only genotypic group with significant differences after multiple‐test correction with a false discovery rate of 0.05 was the frameshift/frameshift genotypic group; these patients were more likely to require full TPN (16 of 16 patients; uncorrected *P*‐value 0.000347; *G*‐test) and be deceased (eight of 16 patients; uncorrected *P*‐value 0.000473; *G*‐test). Thus, these patients are associated with worse clinical outcomes and potentially more severe disease.

![Quantitative distribution genotypes in the current literature. Colors denote current treatment status or clinical outcome of patients with the indicated genotype; each patient is represented by a single box. Transplanted patients who were deceased are reported as transplanted](HUMU-40-142-g005){#humu23688-fig-0005}

The small number of characterized patients and the presence of relatively large numbers of compound heterozygotes complicate the use of statistical tests like the *G*‐test and chi‐squared test for correlating individual mutations with disease severity. We therefore performed random (Monte Carlo) permutation tests in silico to look for individual classes of mutations (frameshift, nonsense, missense, and splice defect) in genotypes associated with the surrogate markers of disease severity. These analyses assume that mutations that would cause more severe disease in homozygote patients will tend to be somewhat more deleterious in compound heterozygotes and that mutations causing less severe disease will also influence severity in compound heterozygotes. In each trial of this simulation, the 68 nutritional (weaned, partial TPN, or full TPN), transplant (yes or no), and mortality (yes or no) outcomes were randomly distributed among the 68 patient genotypes. In other words, the clinical outcomes were randomly permuted in each round; permutation tests are useful nonparametric methods of hypothesis testing when null hypotheses are difficult or impossible to obtain (Fisher, [1935](#humu23688-bib-0023){ref-type="ref"}; Pitman, [1937](#humu23688-bib-0083){ref-type="ref"}; Pitman, [1938](#humu23688-bib-0084){ref-type="ref"}). These random trials were run 10 million times. For each nutritional, transplant, and mortality outcome, a distribution of the number of times the mutation of interest was associated with the outcome was generated. These distributions are null distributions that assumed the clinical outcomes were independent of the mutations in the genotypes. These null distributions were then compared to the number of associations of clinical outcomes to mutations in the real data. *P*‐values were calculated by summing the probabilities of all events in the random distribution that were equal to or more extreme than the number of associations in the real data. This simulation strategy accounted for the relative frequencies of the mutations as well as the nonrandom cooccurrence of mutations in the observed patient genotypes. Consistent with the statistical test results for the frameshift/frameshift genotypes, frameshift mutations were more frequently present in genotypes of patients requiring full TPN than predicted by chance (*P* = 0.003; Figure [6](#humu23688-fig-0006){ref-type="fig"}a) and were less frequent in genotypes of patients with partial TPN (*P* = 0.02; Figure [6](#humu23688-fig-0006){ref-type="fig"}a). Frameshift mutations were also more commonly present in patients who were deceased (*P* = 0.002; Figure [6](#humu23688-fig-0006){ref-type="fig"}a). In contrast, splice site mutations were less commonly present in patients requiring full TPN than predicted by chance (*P* = 0.007): more commonly present in patients with partial TPN (*P* = 0.03; Figure [6](#humu23688-fig-0006){ref-type="fig"}a). Neither nonsense mutations nor missense mutations had a statistically significant association with any clinical outcome (Supporting Information Figure [1](#humu23688-supl-0001){ref-type="supplementary-material"}).

![Computer simulation of patient treatment/outcomes suggests a correlation between c.499dupC and more severe disease. (a) The number of times a category of mutation was associated with a particular treatment or outcome (vertical arrow) was compared to the expected distribution based on random simulations (grey bars). Reported *P*‐values are derived from the expected distributions. Statistically significant *P*‐values are in bold. (b) Analysis of individual mutations using random simulation as in panel A. Of the three mutations that could be analyzed, only the c.499dupC mutation had an observed count that was statistically different than the random distribution](HUMU-40-142-g006){#humu23688-fig-0006}

We then used this Monte Carlo simulation strategy to analyze individual mutations. The c.499dupC mutation is present in 13 of the 69 patients for which severity information was available. All 13 patients with c.499dupC were treated with full TPN, which is significantly more TPN treatment relative to the random simulation (*P* = 0.006) and is significantly less partial TPN relative to the random simulation (*P* = 0.019; Figure [6](#humu23688-fig-0006){ref-type="fig"}b). Additionally, the c.499dupC mutation has a significant increase in association with mortality relative to the random simulation (eight of the 13 patients were deceased; *P* = 0.0006). No significant differences were observed for weaning from full TPN (*P* = 0.41) or bowel transplantation (*P* = 0.13) relative to the simulation. Taken together, these data suggest that the c.499dupC is correlated with more aggressive treatment and poorer outcomes, consistent with more severe disease. The c.499dupC frameshift mutation is responsible for the effect of the frameshift class of mutations in the simulation (Figure [6](#humu23688-fig-0006){ref-type="fig"}a) as well as the correlation of frameshift/frameshift genotype with more severe clinical outcomes (10 of 16 frameshift/frameshift genotypes are homozygous c.499dupC mutations; Supporting Information Table [3](#humu23688-supl-0004){ref-type="supplementary-material"}). In contrast, the c.556‐14A\>G mutation (present in 14 of the 69 patients) is not correlated with treatments or outcomes that are significantly different than random simulation for full TPN (*P* = 0.09), partial TPN (*P* = 0.31), weaning (*P* = 0.14), transplant (*P* = 0.81), or mortality (*P* = 0.63) (Figure [6](#humu23688-fig-0006){ref-type="fig"}b). Similarly, the c.491+1G\>A mutation (present in nine of the 69 patients) is also not correlated with significant changes relative to the random simulation for full TPN (*P* = 0.08), partial TPN (*P* = 0.03), weaning (*P* = 0.55), transplant (*P* = 0.31), or mortality *(P* = 0.36) (Figure [6](#humu23688-fig-0006){ref-type="fig"}b). Despite the evidence for frameshift mutations in general, and c.499dupC in specific as being associated with more severe clinical outcomes, establishing clear genotype/phenotype correlations in CTE is complicated by several factors. These factors including the rare occurrence of CTE, the fact that the mutations are often present in compound heterozygotes, and the lack of standard quantitative measures for disease severity. Use of clinical treatment, nutritional status, and outcomes to characterize disease is also confounded by the individual circumstances of the patient as well as the resources, experiences, and biases of the treatment centers. The limitations of these analyses argue that the development of a quantitative measure for CTE severity will be necessary to establish genotype--phenotype correlations and inform patient treatment and prognosis.

7.2. Genotype--phenotype correlations in Lynch syndrome {#humu23688-sec-0160}
-------------------------------------------------------

In *EPCAM*‐associated Lynch syndrome, epigenetic silencing of *MSH2* is tissue specific, giving rise to mosaic inactivation of *MSH2*, the high risk of colorectal cancer, and the low risk of endometrial cancer (Dymerska et al., [2017](#humu23688-bib-0019){ref-type="ref"}; Kempers et al., [2011](#humu23688-bib-0046){ref-type="ref"}; Lynch et al., [2011](#humu23688-bib-0065){ref-type="ref"}; Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}). In contrast, deletions that span both *EPCAM* and *MSH2* or span regions close to the *MSH2* promoter give rise to high risk for both colorectal and endometrial cancers like mutations in *MSH2* alone (Kempers et al., [2011](#humu23688-bib-0046){ref-type="ref"}).

8. FUTURE PROSPECTS {#humu23688-sec-0170}
===================

*EPCAM* is involved in different ways in three clinically relevant diseases.

8.1. Congenital tufting enteropathy {#humu23688-sec-0180}
-----------------------------------

The fact that CTE appears to be a disease caused by relative loss‐of‐function mutations places constraints on the strategies that can be adopted for long‐term therapy that weans patients from TPN. If EpCAM functioned to suppress another competing mechanism, then pharmacological intervention of the competing mechanism could be pursued, such as use of matriptase inhibitors in the proposed SPINT2/matriptase mechanism (Wu et al., [2017](#humu23688-bib-0131){ref-type="ref"}). Bowel transplant has been used successfully (Paramesh et al., [2003](#humu23688-bib-0079){ref-type="ref"}); however, transplants are complicated by the availability of donors, the need to prevent transplant rejection, and the high rate of posttransplantation mortality. Though technology is still evolving, intestinal stem cell transplantation may be the next generation of transplant strategy for CTE and other monogenic intestinal failure (Hong, Dunn, Stelzner, & Martin, [2017](#humu23688-bib-0040){ref-type="ref"}). Mutations affecting EpCAM mRNA splicing are relatively common in the population. Some strategies for restoration of aberrant splicing in Duchenne muscular dystrophy and spinal muscular atrophy (Benchaouir, Robin, & Goyenvalle, [2015](#humu23688-bib-0009){ref-type="ref"}; Hua et al., [2010](#humu23688-bib-0041){ref-type="ref"}; Hua, Vickers, Okunola, Bennett, & Krainer, [2008](#humu23688-bib-0042){ref-type="ref"}; Kole, Krainer, & Altman, [2012](#humu23688-bib-0049){ref-type="ref"}; Wu et al., [2017](#humu23688-bib-0131){ref-type="ref"}) might be applicable in a subset of CTE patients. A more broadly useful strategy may be to use gene therapy to correct the single nucleotide insertion, deletions, and changes that dominate the CTE patient population. In this regard, the fact that gene therapy may only need to act on cells in the intestinal epithelium may prove to be an advantage; however, it remains an open question as to the level of gene correction that would be required to ameliorate CTE symptoms.

Even in the absence of molecular therapies for CTE, a more pressing concern is the timely diagnosis of infants in order to initiate appropriate treatments as soon as possible. The difficult and lengthy process of histological diagnosis, often requiring repeated endoscopies, is less than ideal. Despite recent immunohistochemical staining advances, including gastric and colonic biopsies when small bowel biopsies are inconclusive, the accuracy and speed remain a limitation of this diagnostic modality (Ranganathan, Schmitt, & Sindhi, [2014](#humu23688-bib-0086){ref-type="ref"}; Treetipsatit & Hazard, [2014](#humu23688-bib-0114){ref-type="ref"}). Conversely, modern genetic analyses have the promise of accelerating the diagnostic pathway and distinguishing CTE patients from those suffering from other congenital enteropathies (Thiagarajah et al., [2018](#humu23688-bib-0112){ref-type="ref"}).

Modern genetic testing methodologies have the advantage of rapidly identifying known mutations and will be particularly useful for the commonly observed mutations. However, the fact that 13 novel mutations were identified in 17 sequenced patients, many of whom were from families without consanguinity, argues that relying solely on previously identified *EPCAM* mutations for diagnosis could lead to many false negatives. Thus, genetic strategies should focus on sequencing of the *EPCAM* gene, potentially using modern short‐read DNA sequencing combined with exon‐capture technologies, and analysis of exon copy number to identify deletions, potentially using read depth from DNA sequencing, microarray comparative genomic hybridization, or MLPA (Gibriel & Adel, [2017](#humu23688-bib-0030){ref-type="ref"}). One advantage of this strategy is that any source of high quality genomic DNA, such as blood, can be used for the analysis. We are hopeful that with continued vigilance in sequencing patients and reporting mutations and associated treatment regimens, genotyping will not only diagnose CTE but also provide physicians the ability to better inform families for diagnosis, family planning, and ultimately cater specific treatment regimens.

8.2. Lynch syndrome {#humu23688-sec-0190}
-------------------

Usually, *EPCAM*‐associated Lynch syndrome is treated as classic Lynch syndrome with aggressive colorectal cancer surveillance, genetic counseling, and assessment of first‐degree relatives. As described above, most *EPCAM*‐associated Lynch syndrome mutations have a high risk of colorectal cancer and a low risk of endometrial cancer unless the *MSH2* gene is also affected (Dymerska et al., [2017](#humu23688-bib-0019){ref-type="ref"}; Kempers et al., [2011](#humu23688-bib-0046){ref-type="ref"}; Lynch et al., [2011](#humu23688-bib-0065){ref-type="ref"}; Perez‐Cabornero et al., [2011](#humu23688-bib-0082){ref-type="ref"}). In theory, this suggests that women with *EPCAM*‐associated Lynch syndrome without deletions affecting *MSH2* should be focused primarily on colorectal cancers and may not need to undergo aggressive surveillance for endometrial cancer or prophylactic hysterectomy (Schmeler et al., [2006](#humu23688-bib-0094){ref-type="ref"}). In practice, general screening guidelines remain conservative and do not take the nuanced genetic difference into account.

Because *EPCAM*‐associated Lynch syndrome is often caused by silencing of an otherwise functional *MSH2* gene, it is possible to envision that treatments that modify the *MSH2* promoter hypermethylation or prevent the read‐through transcription of *EPCAM* and *MSH2* genes could preserve *MSH2* function and could act as a cancer prevention strategy. Such epigenetic approaches are being investigated for use in chemotherapy. For example, 5‐azacytidine (Aza) and Zebularine are cytosine analogs that have been shown to cause reduced DNA methylation through degradation of a trapped drug‐DNA methylase enzyme complex (Heerboth et al., [2014](#humu23688-bib-0036){ref-type="ref"}). Zebularine has been used to reactivate the silenced and hypermethylated *p16* tumor suppressor in a murine model (Cheng et al., [2003](#humu23688-bib-0014){ref-type="ref"}). Additionally, antisense targeting of the DNMT1 DNA methylase also can cause reexpression of a silenced *p16* gene and has been used in the treatment of an advanced renal cell carcinoma (Amato, [2007](#humu23688-bib-0003){ref-type="ref"}). Currently, DNA methylation inhibitors are being developed for chemotherapy and not for cancer suppression; careful analysis of any toxic side effects during long‐term administration would need to be evaluated against any potential benefit in the suppression of tumor formation in Lynch syndrome caused by epigenetic silencing of *MSH2*.

Lynch syndrome is a disease in which a personalized medicine approach is feasible. Clinical history coupled with molecular tumor screening of a patient\'s colon carcinoma can lead to genetic testing and confirmation of Lynch syndrome in a patient and family members. Understanding of genetics, *EPCAM* associated or not, can directly inform the need for invasive and costly measures such as endometrial cancer screening and hysterectomy (Kempers et al., [2011](#humu23688-bib-0046){ref-type="ref"}). Further studies are needed to assess the impact, practicality, and cost‐effectiveness of such approaches, given complex circumstances and treatment strategies (Guglielmo, Staropoli, Giancotti, & Mauro, [2018](#humu23688-bib-0035){ref-type="ref"}).

8.3. *EPCAM* as a tumor marker and a cancer therapy target {#humu23688-sec-0200}
----------------------------------------------------------

EpCAM, the tumor antigen first identified with monoclonal antibodies (Herlyn et al., [1979](#humu23688-bib-0038){ref-type="ref"}), is expressed at high levels in many different adenocarcinomas and squamous cell carcinomas (Fang et al., [2017](#humu23688-bib-0021){ref-type="ref"}; Pan et al., [2018](#humu23688-bib-0078){ref-type="ref"}; Quak et al., [1990](#humu23688-bib-0085){ref-type="ref"}; Went et al., [2004](#humu23688-bib-0128){ref-type="ref"}), and has been suggested to be a cancer stem cell marker (Imrich, Hachmeister, & Gires, [2012](#humu23688-bib-0044){ref-type="ref"}). EpCAM has a role in promoting cell proliferation (Maetzel et al., [2009](#humu23688-bib-0066){ref-type="ref"}). EpCAM expression in a tumor is associated with poor prognosis in breast, ovarian, esophageal, and gallbladder cancer (Spizzo et al., [2004](#humu23688-bib-0108){ref-type="ref"}; Spizzo et al., [2006](#humu23688-bib-0109){ref-type="ref"}; Stoecklein et al., [2006](#humu23688-bib-0110){ref-type="ref"}; Trzpis et al., [2007](#humu23688-bib-0116){ref-type="ref"}; Varga et al., [2004](#humu23688-bib-0121){ref-type="ref"}) but is associated with somewhat improved prognosis in some colonic, gastric, and renal cancers (Seligson et al., [2004](#humu23688-bib-0097){ref-type="ref"}; Songun et al., [2005](#humu23688-bib-0106){ref-type="ref"}; Went et al., [2005](#humu23688-bib-0126){ref-type="ref"}; Went et al., [2006](#humu23688-bib-0127){ref-type="ref"}). EpCAM appears to promote cell proliferation in multiple studies involving both up‐ and downregulation of expression (Chaves‐Perez et al., [2013](#humu23688-bib-0013){ref-type="ref"}; Maetzel et al., [2009](#humu23688-bib-0066){ref-type="ref"}; Munz et al., [2004](#humu23688-bib-0071){ref-type="ref"}; Wenqi et al., [2009](#humu23688-bib-0125){ref-type="ref"}), which is due to the release of the intracellular C‐terminal domain of the protein (EplCD) by the tumor necrosis factor‐α‐converting enzyme and presenilin‐2 proteases. The EplCD fragment becomes localized to the nucleus and induces gene transcription effects that are oncogenic in immunodeficient mice (Maetzel et al., [2009](#humu23688-bib-0066){ref-type="ref"}). Overexpression of EpCAM has also been suggested to play a role in metastasis, due to a role of EpCAM in disrupting cell adhesion and promoting cell migration and cell invasion (Osta et al., [2004](#humu23688-bib-0077){ref-type="ref"}; Winter et al., [2003](#humu23688-bib-0130){ref-type="ref"}), which is consistent experiments in rats demonstrating that overexpression promotes metastases (Wurfel et al., [1999](#humu23688-bib-0133){ref-type="ref"}). As a molecule found at the surface of cancer cells, immunotherapies and antibody‐drug conjugates targeting EpCAM have been investigated for treating cancers (Baeuerle & Gires, [2007](#humu23688-bib-0004){ref-type="ref"}; Lund et al., [2014](#humu23688-bib-0063){ref-type="ref"}; Miller et al., [2016](#humu23688-bib-0068){ref-type="ref"}; Moldenhauer et al., [2012](#humu23688-bib-0069){ref-type="ref"}), including catumaxomab, which has been approved for the treatment of malignant ascites from epithelial cancers (Linke, Klein, & Seimetz, [2010](#humu23688-bib-0059){ref-type="ref"}). Additionally, immunotherapies targeting EpCAM might also function to reduce the formation of metastases in some cancers of epithelial origin. Moreover, EpCAM processing is also an EpCAM‐related cancer therapy target based on the fact that inhibition of the proteolysis inhibits growth signaling (Maetzel et al., [2009](#humu23688-bib-0066){ref-type="ref"}), and screening in an experimental setting has identified a number of potential inhibitors (Tretter et al., [2018](#humu23688-bib-0115){ref-type="ref"}). These observations suggest that adjuvant treatments targeting EpCAM biology may have the potential to broadly target epithelial tumors of different origins.

EpCAM\'s unique role in three disease states likely stems from its multifaceted role in depending on the tissue of interest and *EPCAM* variants and expression. Ongoing vigilance to report and correlate variants to clinical outcomes is necessary to inform understanding of disease progression and potential treatment strategies. Though the last two decades have led to numerous novel insights, many further studies are necessary to translate this knowledge to the bedside.
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**Figure S1. Computer simulation of patient treatment/outcomes for mutations grouped by category**. The number of times a category of mutation was associated with a particular treatment or outcome (vertical arrow) was compared to the expected distribution based on random simulations (grey bars). Reported p‐values are derived from the expected distributions. Statistically significant p‐values are in boxed. Frameshift mutations were correlated with more severe treatment/outcome, whereas splice site mutations were correlated with less aggressive treatment.
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